CEO’S LETTER
Bold and bigger steps for patients

AYMERIC LECHATELIER | CEO & CF
  • 2019 was an important year for Ipsen. What were some of the highlights?

    Aymeric Le Chatelier: 2019 was a pivotal year for Ipsen as a leading global biopharmaceutical company focused on innovation and Specialty Care. Our focus on developing new solutions for targeted debilitating diseases continues to benefit patients and improve their lives through innovative medicines in Oncology, Neuroscience, Rare Diseases and Consumer HealthCare.

  • How important is it for you as a company to put your patients first?

    AC: We are committed to a future where patients have access to life-changing treatments for hard-to-treat cancers, complex rare diseases and severe neurological conditions, a future where we make no compromises and no patient is left behind.

  • As we are completing this interview, COVID-19 is sweeping across the world. What are your priorities in these unprecedented times and how are you supporting COVID-19 relief efforts?

    AC: Right from the very beginning, we established at Ipsen a cross-functional global crisis management team to continually assess the evolution of the pandemic and take the appropriate actions. Our priorities are clear: ensure the health and safety of our colleagues around the world while focusing on business continuity so that patients can access the medicines they need.

Download the full report

PATIENT STORIES
We listen to and learn from patients

A chance for
Nadine

Nadine was 13 when she was diagnosed with fibrodysplasia ossificans progressiva (FOP)

Play video

A chance for
Josep

Josep's liver cancer was discovered two years ago

Play video

A chance for
Diana

Diana was 34 when she had a stroke

Play video

OUR COMMITMENT
An authentic dialogue with our stakeholders

Creating long-term value for all stakeholders

Ipsen puts patients first and acts to provide concrete responses to the needs and expectations of a wide variety of stakeholders, particularly those in healthcare. Ipsen maintains transparent and regular dialogue with its main stakeholders.

Our materiality matrix assessment

In 2019, for the first time, we decided to perform a materiality analysis assessing the expectations of our main stakeholders in terms of Company Social Responsibility. To reflect our specific contribution to the 2030 United Nations Agenda for Sustainable Development, we have aligned our CSR expectations with the United Nations Sustainable Development Goals.

Living our commitment to CSR

In addition to our commitment to improving patients’ lives around the world, Ipsen is also firmly dedicated to protecting the environment and supporting society and the communities in which we operate. We remain dedicated to promoting ethical, responsible and transparent professional practices.

Our people are the key to Ipsen’s success

What sets us apart is our patient-and people-centric approach. At Ipsen, we always strive to put patients first, but we can’t do that without our people. Around the world we have almost 6,000 colleagues and we care about the growth and development of each and every one of them.

Download the full report

Key Figures
2019 indicators

  • 2.35M

    Company sales
    +14.8%* compared to 2018
    * Year-on-year growth excluding foreign exchange impact established by recalculating net sales for the relevant period at the rate used for the previous period. Sales growth adjusted for consolidation scope

  • 782.6M

    OPERATING INCOME
    Core operating margin at 30.4% of net sales

  • 389M

    R&D Investment
    15.1% of 2019 sales

  • 89%

    Specialty Care sales
    within Group sales

  • 11%

    Consumer HealthCare sales
    within the Group sales